Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months

Condition(s) studied

Investigational drug(s) / intervention(s)

Prasugrel: Prasugrel during 12 months

Ticagrelor: Ticagrelor plus aspirin

Study summary

This study is testing different blood-thinning treatment strategies for people who have had a heart attack and were successfully treated with a coronary stent procedure (PCI). All strategies tested are already approved for this condition and used inversally. This study will define which of the approved strategies is the best one.

After PCI, patients usually receive two antiplatelet medicines for up to 12 months to help prevent another heart attack or stroke, but this treatment can also increase bleeding risk. This study will compare a shorter course of dual antiplatelet therapy followed by one antiplatelet medicine alone versus the standard 12-month course. In addition, the study will compare two commonly used antiplatelet drugs, prasugrel and ticagrelor. The goal is to find out which strategy best prevents death, heart attack, or stroke while minimizing serious bleeding.

This study is not testing any new intervention, rather comparing approved drugs and approved durations of use.

Eligibility

Primary outcome measure(s)

• ischemic events — 12 months
  incidence of the composite of "all-cause death, reinfarction or stroke"

Trial sites (5)

On this site

Other trials for the same condition